ARV-6723 / Arvinas - LARVOL DELTA

ARV-6723: Oral PROTAC HPK1 degrader (Arvinas Press Release) - "Present preclinical data at the Society for Immunotherapy of Cancer Annual Meeting (Nov. 8, 2025); Initiate Phase 1 clinical trial in patients with advanced solid tumors, pending regulatory feedback (2026)."

New P1 trial • Preclinical • Solid Tumor

Preclinical antitumor activity of potent and orally bioavailable PROTAC hematopoietic progenitor kinase 1 (HPK1) degraders as monotherapy or combined with an anti-programmed death-1 (PD-1) antibody (SITC 2025) - "These results support future investigation of PROTAC HPK1 degraders alone or combined with other agents in patients with certain cancers.Ethics Approval Animals were maintained in accordance with the guidelines of the Guide for the Care and Use of Laboratory Animals. All animal research protocol procedures were reviewed and approved by the Arvinas Animal Care and Use Committee."

Monotherapy • Preclinical • Melanoma • Oncology • Solid Tumor • IL2